Omecamtiv Mecarbil在心力衰竭治疗中的研究进展  

Research Progress of Omecamtiv Mecarbil in Treatment of Heart Failure

作　　者：王灿 韦利穆 董小英[1] 富路[1] WANG Can;WEI Limu;DONG Xiaoying;FU Lu(Department of Cardiology,The First Affiliated Hospital of Harbin Medical University,Harbin 150001,Heilongjiang,China)

机构地区：[1]哈尔滨医科大学附属第一医院心血管内科三病房,黑龙江哈尔滨150001

出　　处：《心血管病学进展》2018年第6期979-982,共4页Advances in Cardiovascular Diseases

摘　　要：收缩性心力衰竭有着极高的发病率和死亡率,而可用于心力衰竭治疗的药物在安全性和有效性方面都受到限制。Omecamtiv Mecarbil作为一种心肌肌球蛋白激活剂,可直接激活心肌细胞内的酶途径,导致心室收缩。这种独特的正性肌力药物已经在临床前和临床研究中显示出,可通过增加收缩期射血时间、每搏输出量等有效改善心脏功能,而不会产生类似于其他间接正性肌力药物的不良影响,心肌肌球蛋白激活剂有望成为治疗收缩性心力衰竭更安全和更有效的方法。Systolic heart failure causes significant morbidity and mortality.Available pharmacologic treatments for heart failure are limited in both safety and effectiveness.Cardiac myosin activators,specifically omecamtiv mecarbil,directly activate the enzymatic pathway within the cardiac myocyte leading to ventricular contraction.This unique inotropic agent has been shown in preclinical and clinical studies to be effective in improving cardiac contractility by increasing systolic ejection time and stroke volume without the unwanted effects of the currently available indirect inotropic drugs.Cardiac myosin activators may prove to be a safer and more effective therapeutic approach for the treatment of systolic heart failure.

关 键 词：Omecamtiv Mecarbil 心力衰竭 心肌肌球蛋白激动剂 

分 类 号：R541.6[医药卫生—心血管疾病]